Rates of malignancy associated with juvenile idiopathic arthritis and its treatment
Authors:
- Timothy BeukelmanTBTimothy Beukelman
- Kevin HaynesKHKevin Haynes
- Fenglong XieFXFenglong Xie
- Lang ChenLCLang Chen
- Christina J. Bemrich‐StolzCBChristina J. Bemrich‐Stolz
- Elizabeth DelzellEDElizabeth Delzell
- Kenneth G. SaagKSKenneth G. Saag
- Safety Assessment of Biological Therapeutics CollaborationSCSafety Assessment of Biological Therapeutics Collaboration
Open Access
- 10 February 2012
- journal article
- pediatric rheumatology
- Published by Wiley in Arthritis & Rheumatism
- Vol. 64 (4) , 1263-1271
Abstract
Objective: To determine the relative rates of incident malignancy among children with juvenile idiopathic arthritis (JIA) with respect to treatment as compared to children without JIA.Methods: Using national Medicaid data from 2000 through 2005, we identified cohorts of children with JIA and without JIA according to the diagnosis codes used by their physicians and the medication prescriptions that were dispensed. Study followup began after a 6‐month lag period to exclude prevalent and misdiagnosed malignancies. Treatment with methotrexate (MTX) and tumor necrosis factor (TNF) inhibitors was categorized as ever exposed or never exposed. Malignancy outcomes were identified using an adapted version of a previously validated algorithm. Incident malignancies were categorized as possible, probable, or highly probable based on a comprehensive review of all claims. Malignancy rates were standardized to the age, sex, and race distribution of the overall JIA cohort. Standardized incidence ratios (SIRs) were calculated using children with attention deficit hyperactivity disorder (n = 321,821) (one of two comparator groups included) as the referent group.Results: The JIA cohort included 7,812 children with a total followup time of 12,614 person‐years; 1,484 of these children contributed 2,922 person‐years of TNF inhibitor exposure. For all children with JIA versus children without JIA, the SIR was 4.4 (95% confidence interval [95% CI] 1.8–9.0) for probable and highly probable malignancies. For those taking MTX without TNF inhibitor use, the SIR was 3.9 (95% CI 0.4–14). Following any use of TNF inhibitors, no probable or highly probable malignancies were identified (SIR 0 [95% CI 0–9.7]).Conclusion: Children with JIA appeared to have an increased rate of incident malignancy compared to children without JIA. The treatment for JIA, including TNF inhibitors, did not appear to be significantly associated with the development of malignancy.Keywords
This publication has 33 references indexed in Scilit:
- Malignancies in Juvenile Idiopathic Arthritis: A Preliminary Report: Table 1.The Journal of Rheumatology, 2011
- Juvenile idiopathic arthritis and risk of cancer: A nationwide cohort studyArthritis & Rheumatism, 2010
- Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?Pediatric Rheumatology, 2010
- Should the food and drug administration warning of malignancy in children receiving tumor necrosis factor α blockers change the way we treat children with juvenile idiopathic arthritis?Arthritis & Rheumatism, 2010
- Anti–tumor necrosis factor therapy and cancer risk in patients with autoimmune disordersArthritis Care & Research, 2010
- Monitoring the long‐term safety of therapies for children with juvenile idiopathic arthritis: Time for a consolidated patient registryArthritis Care & Research, 2010
- Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extensionAnnals of the Rheumatic Diseases, 2010
- A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritisArthritis Research & Therapy, 2008
- Under-Reporting of Adverse Drug ReactionsDrug Safety, 2006
- A review of uses of health care utilization databases for epidemiologic research on therapeuticsJournal of Clinical Epidemiology, 2005